The European Medicines Agency (EMA) said on Monday it would no longer post on X and would use rival Bluesky instead, becoming the latest organisation to quit a social media platform that some have criticised for its content.

During the trading session on Tuesday, we saw the euro dropped rather significantly. In fact, we are below the 50 Day EMA, the course is

The use of the ESMP will become mandatory for MAHs and NCAs as of Sunday, February 2. The platform is a key requirement of the European Medicines Agency’s extended mandate, enhancing shortages monitoring and preparedness across the European Union (EU)/European Economic Area (EEA).

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here.

The government agency says X no longer suits its communication needs.

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorisation Application, MAA, for the use

The European Medicines Agency (EMA) has decided to stop using the social media platform X due to content concerns and will instead use Bluesky. This move aligns with other organizations stepping back from X,

Paracetamol, now comes with a shocking new warning: it could lead to a dangerous condition called metabolic acidosis if misused or overused.

GSK has announced that the European Medicines Agency (EMA) has accepted its regulatory application for a prefilled syringe presentation of Shingrix

The EMA is implementing major changes to accelerate drug approvals in the EU, addressing delays that affect patients and businesses alike. Following a turbulent period marked by Brexit and the ...

"The calculations have shown a possible drop in prices for patients in total for both prescription and over-the-counter medicines by up to 20%,” Abu Meri told Euractiv.

KDEV) today announces that its portfolio company Dilafor has successfully completed regulatory meetings with the U.S. Food and Drug Administration, FDA, and European Health Agencies, regarding the continued development of the company’s drug candidate tafoxiparin.